Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Exagen Inc. XGN
$2.87
-$0.03 (-1.03%)
На 18:02, 12 мая 2023
+143.90%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
49383140.00000000
-
week52high
8.96
-
week52low
2.04
-
Revenue
45563000
-
P/E TTM
-1
-
Beta
1.25484700
-
EPS
-2.69000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 мая 2023 г. в 20:00
Описание компании
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody and associated vasculitis; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Keybanc | Overweight | Overweight | 13 мая 2022 г. |
| Keybanc | Overweight | Overweight | 25 мар 2022 г. |
| Keybanc | Overweight | Overweight | 11 ноя 2021 г. |
| Canaccord Genuity | Buy | 15 апр 2021 г. | |
| KeyBanc | Overweight | Overweight | 02 мар 2021 г. |
| Canaccord Genuity | Buy | Buy | 15 ноя 2022 г. |
| BTIG | Buy | Buy | 17 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| ABALLI JOHN | A | 440000 | 90000 | 08 дек 2022 г. |
| ABALLI JOHN | A | 350000 | 350000 | 16 окт 2022 г. |
| Stokes Frank | A | 9000 | 9000 | 16 июн 2022 г. |
| Birk Brian | A | 9000 | 9000 | 16 июн 2022 г. |
| Hooker Ana | A | 9000 | 9000 | 16 июн 2022 г. |
| TULLIS JAMES L L | A | 9000 | 9000 | 16 июн 2022 г. |
| Nova Tina Susan | A | 9000 | 9000 | 16 июн 2022 г. |
| PALLARES EBETUEL | A | 9000 | 9000 | 16 июн 2022 г. |
| Johnson Wendy S. | A | 9000 | 9000 | 16 июн 2022 г. |
| Rocca Fortunato R. | D | 120678 | 4322 | 01 мар 2022 г. |
Новостная лента
Exagen Inc. (XGN) CEO John Aballi on Q3 2022 Results - Earnings Call Transcript
Seeking Alpha
14 ноя 2022 г. в 22:25
Exagen Inc. (NASDAQ:XGN ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Ryan Douglas - IR John Aballi - President and CEO Kamal Adawi - CFO Mark Hazeltine - Chief Operating Officer Conference Call Participants Max Masucci - Cowen & Company Griffin Soriano - William Blair Kyle Mikson - Canaccord Genuity Operator Greetings, and welcome to the Exagen Inc. Third Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode.
Exagen Inc. (XGN) Reports Q3 Loss, Tops Revenue Estimates
Zacks Investment Research
14 ноя 2022 г. в 21:03
Exagen Inc. (XGN) delivered earnings and revenue surprises of 38.16% and 61.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Exagen to Announce Third Quarter 2022 Financial Results on November 14, 2022
GlobeNewsWire
31 окт 2022 г. в 16:05
SAN DIEGO, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended September 30, 2022, after the market close on Monday, November 14, 2022. John Aballi, Exagen's President and Chief Executive Officer, Kamal Adawi, Chief Financial Officer, and Mark Hazeltine, Chief Operating Officer, will host a conference call to review the Company's results at 4:30 PM ET (1:30 PM PT).
Exagen Inc. (XGN) CEO Ron Rocca on Q2 2022 Results - Earnings Call Transcript
Seeking Alpha
06 авг 2022 г. в 13:08
Exagen Inc. (NASDAQ:XGN ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Ryan Douglas - Investor Relations Ron Rocca - President and Chief Executive Officer Kamal Adawi - Chief Financial Officer Conference Call Participants Griffin Soriano - William Blair Ross Osborn - Cantor Fitzgerald Ryan Douglas Good afternoon, and thank you for joining us today. Earlier today, Exagen Inc. released financial results for the quarter ended June 30th, 2022.
Exagen to Announce Second Quarter 2022 Financial Results on August 4, 2022
GlobeNewsWire
21 июл 2022 г. в 16:05
SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended June 30, 2022, after the market close on Thursday, August 4, 2022. Ron Rocca, Exagen's President and Chief Executive Officer, Kamal Adawi, Chief Financial Officer, and Mark Hazeltine, Chief Operating Officer, will host a conference call to review the Company's results at 4:30 PM ET (1:30 PM PT).